报价延迟最少15分钟:2026/01/09 22:04 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.72 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1,229.73/-1.18
|
|
企业价值
2.67M
|
| 资产负债 |
|
每股账面净值
2.17
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
